LIPELLA PHARMACEUTICALS INC. financial data

Symbol
LIPO on OTC
Location
Pittsburgh, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 444 % -11.3%
Debt-to-equity 33 % +33.5%
Return On Equity -208 % -8.39%
Return On Assets -157 % -1.65%
Operating Margin -1.19K % -41.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.62M shares +282%
Common Stock, Shares, Outstanding 4.62M shares +323%
Entity Public Float 2.62M USD -72.7%
Common Stock, Value, Issued 462 USD +324%
Weighted Average Number of Shares Outstanding, Basic 4.55M shares +306%
Weighted Average Number of Shares Outstanding, Diluted 4.55M shares +306%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 470K USD -7.3%
Research and Development Expense 3.57M USD +18.7%
General and Administrative Expense 2.23M USD +21.4%
Operating Income (Loss) -5.41M USD -24.1%
Nonoperating Income (Expense) 80.2K USD -15.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.33M USD -25%
Net Income (Loss) Attributable to Parent -5.33M USD -25%
Earnings Per Share, Basic -2 USD/shares +67.4%
Earnings Per Share, Diluted -2 USD/shares +67.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.86M USD +37.1%
Accounts Receivable, after Allowance for Credit Loss, Current 84.7K USD +162%
Assets, Current 2.08M USD -0.03%
Property, Plant and Equipment, Net 7.7K USD -27.3%
Operating Lease, Right-of-Use Asset 263K USD +278%
Assets 2.35M USD +8.78%
Accounts Payable, Current 463K USD +0.75%
Accrued Liabilities, Current 34.9K USD -61.1%
Liabilities, Current 642K USD -8.38%
Operating Lease, Liability, Noncurrent 220K USD
Liabilities 862K USD +23%
Retained Earnings (Accumulated Deficit) -19.2M USD -38.3%
Stockholders' Equity Attributable to Parent 1.49M USD +1.97%
Liabilities and Equity 2.35M USD +8.78%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.43M USD -2.71%
Net Cash Provided by (Used in) Financing Activities 3.47M USD +1633%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 4.62M shares +323%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.86M USD +37.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.15K USD -33.4%
Deferred Tax Assets, Valuation Allowance 4.22M USD +47.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 4.22M USD +47.7%
Operating Lease, Liability 23.8K USD +45.1%
Operating Lease, Liability, Current 44.3K USD -37.5%
Deferred Tax Assets, Operating Loss Carryforwards 1.79M USD +54.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 20.7M USD +34.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 722 USD +0.14%
Operating Leases, Future Minimum Payments Due 311K USD +327%
Interest Expense 17.2K USD +233%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%